2022-502455-57-01CompletedPhase 2
Glucagon enhanced insulin absorption in Diabetes Mellitus type 1
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Mar 2023
Brief summary (registry, in English)
To investigate if micro-doses of glucagon at the same site as subcutaneous insulin delivery enhances the absorption of insulin and reduces postprandial glucose excursions in patients with diabetes mellitus type 1
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 20 Mar 2023
- Start date
- 20 Jun 2023
- Lead sponsor
- St. Olavs Hospital HF
- Diseases
- Type 1 diabetes
- EU CT number
- 2022-502455-57-01
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 30
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any chronic disease, including psychiatric illnesses, judged incompatible with participation in the study.
- Known hypersensitivity to glucagon or any of the excipients of the drug formulation
Other
- Pregnant women or women trying to conceive (women will not be screened by a pregnancy test).
- Unfit for participation for any reason as judged by the investigators
- Known phaeochromocytoma
Who the study is looking for
- DM1 for at least 1 year.
- Age 18 – 70 years
- Last known HbA1c <86 mmol/mol (< 10.0%)
- Treated with continuous SC insulin infusion (CSII) by an insulin pump or with multiple daily insulin injections (MDII).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Olavs hospital HF | Trondheim | Norway | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.